One of the most common ICIs targets the lymphocyte immune inhibitory receptor PD-1 (programmed death 1) with monoclonal antibodies (anti-PD-1), thus competing with its ligands programmed death-ligand 1 (PD-L1) and PD-L2, expressed by tumors and immunosuppressive cells, preventing cell anergy and promoting tumor destruction [9,10,11]. Here, PDCD1LG2 is linked to neoplasm.